Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 15,918 matching trials from the live ClinicalTrials.gov search.
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BMS-986504, Izalontamab Brengitecan
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
Anchorage, Alaska • Boston, Massachusetts • Detroit, Michigan + 6 more
Conditions
Untreated Childhood Brain Stem Glioma
Interventions
motexafin gadolinium, radiation therapy, pharmacological study
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Arcadia, California
Conditions
Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm, Malignant Adrenal Gland Neoplasm, Metastatic Liver Carcinoma, Metastatic Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Liver Cancer, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Liver Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Liver Cancer, Stage IVA Lung Cancer AJCC v8, Stage IVB Liver Cancer, Stage IVB Lung Cancer AJCC v8
Interventions
Anti-CTLA4 Monoclonal Antibody BMS-986218, Nivolumab, Stereotactic Body Radiation Therapy
Biological · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neutropenia, Infection
Interventions
Standard antimicrobial therapy, Granulocyte transfusions, G-CSF/dexamethasone, Apheresis machine
Drug · Biological · Device
Lead sponsor
Carelon Research
Other
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
13
States / cities
Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts + 9 more
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
Interventions
Beta blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Terminated Phase 1Phase 2 Interventional Results available

Metabolic Effects of Metformin Therapy in Obstructive Sleep Apnea

NCT04530747
Conditions
Sleep Apnea, Obstructive
Interventions
Metformin + PAP, Placebo oral capsule + PAP
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
35 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Opioid-use Disorder
Interventions
Disclosing Recovery: A Decision Aid and Toolkit, Mindfulness
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Conditions
Iron-deficiency, Heart Failure With Preserved Ejection Fraction
Interventions
Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric], Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Obesity
Interventions
Liraglutide, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Epilepsies, Partial
Interventions
nasal diazepam
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Neuroblastoma
Interventions
3F8 monoclonal antibody and 13-cis-Retinoic Acid
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Months and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Cancer, Tumor
Interventions
Community Health Worker Support
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Conditions
Diabetic Foot Ulcer, Surgical Wound
Interventions
Natrox® Oxygen Wound Therapy
Device
Lead sponsor
Inotec AMD Limited
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Los Angeles, California • Miami, Florida • Miami Lakes, Florida + 15 more
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

NCT00467987
Conditions
Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism
Interventions
androgel, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
31 Years to 60 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Hepatitis C
Interventions
DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV
Drug
Lead sponsor
Timothy Morgan, MD
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Long Beach, California
Recruiting Not applicable Interventional Accepts healthy volunteers

Transcranial Direct Current Stimulation and Modulation of Affect and Pain

NCT06989749
Conditions
We Are Not Studying a Disease or Condition
Interventions
Anodal tDCS, Cathodal tDCS, Sham tDCS
Other
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Hanover, New Hampshire
Active, not recruiting Phase 1 Interventional

Bevacizumab/Doxorubicin/Radiation for Sarcoma

NCT01746238
Conditions
Sarcoma
Interventions
Bevacizumab, Doxorubicin, Radiation Therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Interventions
Azacitidine Subcutaneous Injection or Intravenous Infusion, Pevonedistat Infusion, Bone Marrow Biopsy & Aspirate
Drug · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Miami, Florida • Westwood, Kansas • New York, New York + 2 more
Conditions
Diabetes Mellitus, Type 1, Diabetes, Diabetes, Autoimmune
Interventions
ILT-101 (Aldesleukin; IL-2), Treatment-Placebo Arm, Placebo Arm
Biological · Other
Lead sponsor
Jay S. Skyler
Other
Eligibility
8 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Conditions
Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
Interventions
(IRIS-CKD Management Program): Education, (IRIS-CKD Management Program): GDMT
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more
Conditions
High-Risk Prostate Cancer
Interventions
Capivasertib, abiraterone acetate
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
West Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 6 more
Conditions
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Bone, Pain
Interventions
External Beam Radiation Therapy, Palliative Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers Results available

Kids SipSmartER, an Intervention to Reduce Sugar-sweetened Beverages

NCT03740113
Conditions
Sugary Beverages
Interventions
Kids SipSmartER
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 85 Years
Enrollment
1,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma
Interventions
rituximab, recombinant interleukin-12, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment
Biological · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota